| Literature DB >> 35083558 |
Murat Kutlu1,2, Selda Sayın-Kutlu3, Sema Alp-Çavuş4, Şerife Barçın Öztürk5, Meltem Taşbakan6, Betil Özhak7, Onur Kaya8, Oya Eren Kutsoylu4, Şebnem Şenol-Akar9, Özge Turhan10, Gülşen Mermut6, Bülent Ertuğrul5, Hüsnü Pullukcu6, Çiğdem Banu Çetin9, Vildan Avkan-Oğuz4, Nur Yapar4, Dilek Yeşim-Metin11, Çağrı Ergin12.
Abstract
Candidemia may present as severe and life-threatening infections and is associated with a high mortality rate. This study aimed to evaluate the risk factors associated with 30-day mortality in patients with candidemia. A multi-center prospective observational study was conducted in seven university hospitals in six provinces in the western part of Turkey. Patient data were collected with a structured form between January 2018 and April 2019. In total, 425 episodes of candidemia were observed during the study period. Two hundred forty-one patients died within 30 days, and the 30-day crude mortality rate was 56.7%. Multivariable analysis found that SOFA score (OR: 1.28, CI: 1.154-1.420, p < 0.001), parenteral nutrition (OR: 3.9, CI: 1.752-8.810, p = 0.001), previous antibacterial treatment (OR: 9.32, CI: 1.634-53.744, p = 0.012), newly developed renal failure after candidemia (OR: 2.7, CI: 1.079-6.761, p = 0.034), and newly developed thrombocytopenia after candidemia (OR: 2.6, CI: 1. 057-6.439, p = 0.038) were significantly associated with 30-day mortality. Central venous catheter removal was the only factor protective against mortality (OR: 0.34, CI:0.147-0.768, p = 0.010) in multivariable analysis. Candidemia mortality is high in patients with high SOFA scores, those receiving TPN therapy, and those who previously received antibacterial therapy. Renal failure and thrombocytopenia developing after candidemia should be followed carefully in patients. Antifungal therapy and removing the central venous catheter are essential in the management of candidemia.Entities:
Keywords: Candida; Candida parapsilosis; Catheter removal; Mortality; Risk factors
Mesh:
Substances:
Year: 2022 PMID: 35083558 DOI: 10.1007/s10096-021-04394-0
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267